Segment Information (Notes)

9 Months Ended

Sep. 30, 2017

Segment Reporting Information [Line Items]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

19. Segment Information

In connection with acquiring 100% of the equity interests of LENSAR in May 2017, the Company added a third reportable segment, “medical devices” and renamed the previous product sales segment “pharmaceutical”.

Information regarding the Company’s segments for the three and nine months endedSeptember 30, 2017 and 2016 is as follows:

Revenues by segment	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in thousands)	2017		2016		2017		2016
Income generating assets	$	42,682	$	39,510	$	200,547	$	163,681
Pharmaceutical	15,104		14,128		43,897		14,128
Medical devices	4,963		—		7,580		—
Total revenues	$	62,749	$	53,638	$	252,024	$	177,809

Income (loss) by segment	Three Months Ended						Nine Months Ended
	September 30,						September 30,
(in thousands)	2017			2016			2017			2016
Income generating assets	$	25,248		$	14,049		$	98,746		$	74,084
Pharmaceutical	1,082			(142		)	(3,560		)	(142		)
Medical devices	(5,598		)	—			(6,774		)	—
Total net income	$	20,732		$	13,907		$	88,412		$	73,942

Long-lived assets by segment
(in thousands)	September 30, 2017		December 31, 2016
Income generating assets	$	145	$	38
Pharmaceutical	860		—
Medical devices	7,125		—
Total long-lived assets	$	8,130	$	38

The operations for the Company’s Pharmaceutical and Medical Devices segments are primarily located in Ireland and the United Stated, respectively.